Home › Free Stock Grades › EYPT
EyePoint Pharmaceuticals, Inc. (EYPT) Stock Grade
EYPT · Healthcare
C+
Market Cap
$1.3B
P/E Ratio
—
Revenue Growth (YoY)
-27.5%
Net Margin
-739.4%
Return on Equity
—
Dividend Yield
None
About EyePoint Pharmaceuticals, Inc.'s fundamentals
EyePoint Pharmaceuticals is a $1.3 billion biotechnology company that reported a significant revenue decline of 27.5% year-over-year, indicating shrinking top-line sales. The company posted a substantial net loss in its latest annual statement, reflected in a negative net margin of -739.4%, meaning it lost $7.39 for every dollar of revenue generated. With no dividend and negative profitability metrics, the company is currently not generating positive returns on shareholder equity.